Seattle researchers need your help in searching for the genes linked to inherited prostate cancer

February 27, 2000

SEATTLE - Scientists at Fred Hutchinson Cancer Research Center and the University of Washington are conducting a search, involving hundreds of families nationwide, to find the genes responsible for inherited prostate cancer (prostate cancer that runs in families).

However, of the nearly 300 families that have participated so far in this genetic family study, only a handful have been African American.

"One limitation of our ongoing research is that few minority families have enrolled," says Dr. Janet Stanford, an epidemiologist at the Hutchinson Center and at UW who oversees recruitment of families involved in the Prostate Cancer Genetic Research Study, or PROGRESS.

Of 292 families participating in the PROGRESS study, only six are non-Caucasian, she says, so the recruitment emphasis during the next year will involve bolstering participation of minority families, particularly African Americans.

"Because African Americans have the highest incidence and mortality from prostate cancer of any group in the world, we think it's important for them to be represented in the study," Stanford says.

Prostate cancer kills about 40,000 American men every year. African Americans have a 60 percent higher risk of developing prostate cancer and a 100 percent higher death rate from the disease as compared with Caucasian Americans. Finding the gene or genes implicated in inherited prostate cancer may provide clues that will eventually help diagnose, treat, cure and even prevent the disease, Stanford says.

At least 100 African-American families are needed to participate in this ongoing study.The researchers, initially supported by a four-year grant from CaP CURE, the Association for the Cure of Cancer of the Prostate, have obtained additional funding from the National Cancer Institute to continue this work.

Fred Hutchinson Cancer Research Center

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to